Aldehyde-Binding Compounds for Non-Invasive MRI Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic technologies lack effective methods for detecting and quantifying aldehydes, particularly in vivo, which are important markers for physiological conditions such as Alzheimer's disease and cancer chemotherapy efficacy, due to invasive sampling and limited detection capabilities under physiological conditions.
Innovation Solution
Development of aldehyde-binding compounds represented by Formula I, which can bind to aldehyde-containing molecules, allowing for detection using imaging techniques like MRI, CEST-MRI, or PET, and enabling fluorescence or electrochemical detection, facilitating non-invasive monitoring of aldehydes in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional detection methods (spectrophotometric methods, post mortem tissue sampling) are used, then aldehyde detection is possible, but the methods are invasive and require post mortem sampling
Solution Approach 1:
The patent employs CEST-MRI as an intermediary detection method that enables non-invasive monitoring of aldehydes in vivo. The technique uses magnetic resonance imaging with chemical exchange saturation transfer to detect aldehyde groups without requiring tissue sampling or invasive procedures, thus resolving the contradiction between detection capability and invasiveness
Solution Approach 2:
The patent replaces traditional mechanical/invasive sampling methods with a non-invasive imaging-based detection system. By substituting physical tissue sampling with magnetic resonance imaging technology, the method eliminates the harmful invasive factor while maintaining aldehyde detection capability
2Object-affected harmful factors
If CEST-MRI is used to detect carbonyls, then non-invasive detection is achieved, but detection of biologically significant functional groups like carbonyls under physiological conditions remains challenging
Solution Approach 1:
The patent modifies the CEST-MRI detection parameters and employs specifically designed contrast agents that are activated by aldehyde binding. This parameter optimization enables reliable detection of carbonyl groups under physiological conditions by adjusting the magnetic resonance imaging parameters to match the biochemical environment, thus resolving the reliability issue while maintaining non-invasive detection
3Adaptability or versatility
If few available aldehyde detection technologies are used, then current limitations are acknowledged, but diagnostic applications for imaging are insufficient
Solution Approach 1:
The patent develops a universal detection platform that combines CEST-MRI imaging capability with aldehyde-specific contrast agents. This multi-functional system enables both non-invasive imaging and specific aldehyde detection, providing diagnostic applications that were previously unavailable, thus resolving the contradiction between technology availability and diagnostic capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive detection and monitoring of aldehydes in biological samples, providing valuable diagnostic and therapeutic insights into conditions like Alzheimer's disease, cancer treatment efficacy, and other physiological processes, with potential applications in imaging and treatment strategies.
Implementation Method 1
compounds that bind carbonyl-containing molecules such as aldehydes and ketones
Implementation Method 2
detecting the product of the compound of Formula I and the aldehyde-containing compound, wherein the detecting employs imaging, such as MRI
Implementation Method 3
Chemical Exchange Saturation Transfer magnetic resonance imaging (CEST-MRI) shows promise in detection of functional groups of physiological interest. CEST-MRI imaging can detect endogenous biomolecules that exchange protons with water
Implementation Method 4
The sample may be a tissue sample or biological fluid sample from a subject. Further, the detecting of the product may comprise using fluorescence
Implementation Method 5
the detecting of the product may comprise using fluorescence or an electrochemical detection method
Data Source
AI summary
Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with the sample; and detecting the product of the compound of Formula I and the aldehyde-containing compound. Detection of the product may involve imaging, such as MRI, CEST-MRI or positron emission tomography (PET) imaging; or may involve fluorescence or an electrochemical detection method. Biologically relevant aldehydes detected according to the described method can be used to monitor conditions such as brain injury, neurodegenerative disorders such as Alzheimer's disease, diabetes, heart disease, and cancer.